Digital Pathology and AI for Liver Outcomes in MASLD (DPAILO-2)

From NCT01030484: * Age at least 18 years during the consent process * Willingness to be in the study for 1 or more years * Ability and willingness to give written, informed consent to be screened for and, if eligible, to be enrolled into the Database 2 study * Minimal or no alcohol use history consistent with NAFLD (see exclusion criteria) * Collection of a liver biopsy that is obtained within 120 days of enrollment as part of standard of care or for evaluation in FLINT trial * Collection of biosamples (serum, plasma, DNA, and, if available, liver tissue) within 90 days prior to enrollment and 0-90 days before or 4-90 days after the standard of care liver biopsy Exclusion Criteria: From NCT01030484 * Clinical or histological evidence of alcoholic liver disease or alcohol consumption during the two years before entry (\> 20g/day for men, \>10g/day women) * History of total parenteral nutrition * History of gastric or jejunoileal bypass preceding the diagnosis of NAFLD * Biliopancreatic diversion or bariatric surgery * Evidence of advanced liver disease with Child-Pugh-Turcotte score equal to or greater than 10 * Short bowel syndrome * Suspected or confirmed hepatocellular carcinoma * Positive for HIV * Evidence of HBV or HCV infection * Low alpha-1-antitrypsin level and ZZ phenotype * Wilson's disease * Known glycogen storage disease, dysbetalipoproteinemia, phenotypic hemochromatosis * Vascular lesions * Iron overload greater than 3+ * Zones of confluent necrosis, infarc…